| 2026-08-13 | Press release | Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-07-27 | Press release | Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the |
| 2026-07-21 | Press release | Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers |
| 2026-07-20 | Press release | Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 |
| 2026-07-08 | Press release | Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 |
| 2026-06-24 | Press release | Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell |
| 2026-06-23 | Press release | Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Director |
| 2026-06-16 | Press release | Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current De |
| 2026-06-08 | Press release | Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 |
| 2026-05-26 | Press release | Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting |
| 2026-05-22 | Press release | Calidi Biotherapeutics Provides Required NYSE American Disclosure |
| 2026-05-14 | Press release | Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights |
| 2026-05-13 | Press release | Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston |
| 2026-04-29 | Press release | Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Proce |
| 2026-04-28 | Presentation | Download(opens in new window) |
| 2026-04-21 | Press release | Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 |
| 2026-04-20 | Press release | Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candi |
| 2026-04-17 | Presentation | Presentation(opens in new window) |
| 2026-04-17 | Presentation | Download(opens in new window) |
| 2026-04-15 | Press release | Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Ad |
| 2026-04-14 | Press release | Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlightin |
| 2026-04-07 | Press release | Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the Red |
| 2026-04-02 | Press release | Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 |
| 2026-04-01 | Press release | Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Can |
| 2026-03-27 | Press release | Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights |
| 2026-03-24 | Press release | Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accel |
| 2026-03-12 | Press release | Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioproce |
| 2026-03-09 | Press release | Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ |
| 2026-03-06 | Press release | Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering |
| 2026-03-05 | Press release | Calidi Biotherapeutics Announces Proposed Public Offering |
| 2026-02-20 | Press release | Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platfor |
| 2026-02-12 | Press release | Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform i |
| 2026-02-09 | Presentation | Corporate Presentation |
| 2026-01-28 | Press release | Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 |